Neurotech International Ltd.

As of June 30, 2025, Neurotech International Ltd. carries a market capitalization of 15.74M, placing it among publicly traded companies globally. Its enterprise value stands at 12.71M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Neurotech International Ltd.'s next confirmed earnings release is scheduled for March 2, 2027.

As of June 30, 2025, Neurotech International Ltd. has 1.05B shares outstanding.

These figures are as of June 30, 2025. The price-to-sales ratio is 65,287.28, and the price-to-book ratio stands at 5.33.

These figures are as of June 30, 2025. The EV/Sales ratio of 53,417.54 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 12.71M versus a market cap of 15.74M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2025, Neurotech International Ltd. maintains a current ratio of 11.34, meaning it holds 11.3x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2025, Neurotech International Ltd. posted a negative return on equity (ROE) of -142.71, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -137.17, reflecting losses generated across the asset base.

As of the close on October 22, 2026, Neurotech International Ltd.'s stock has gained approximately 12.50% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.01.

Over the twelve months ended June 30, 2025, Neurotech International Ltd. generated 238.00 in revenue and converted that into -10.60M in net income, yielding earnings per share of -0.01. EBITDA reached -13.18M, while operating income came in at -13.18M.

These figures are as of June 30, 2025. Total book value stands at 2.95M, with working capital of 2.95M providing operational flexibility.

These figures cover the twelve months ended June 30, 2025. The operating margin of -5.54M and net profit margin of -4.45M provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2025. Total shareholder yield is negative at -2.73, meaning Neurotech International Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Neurotech International Ltd.'s most recent stock split took place on February 5, 2019 with a 7:8 split ratio.

As of June 30, 2025, Neurotech International Ltd. has an Altman Z-Score of -1.80, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.